EA200701741A1 - Композиция, содержащая окаперидон - Google Patents

Композиция, содержащая окаперидон

Info

Publication number
EA200701741A1
EA200701741A1 EA200701741A EA200701741A EA200701741A1 EA 200701741 A1 EA200701741 A1 EA 200701741A1 EA 200701741 A EA200701741 A EA 200701741A EA 200701741 A EA200701741 A EA 200701741A EA 200701741 A1 EA200701741 A1 EA 200701741A1
Authority
EA
Eurasian Patent Office
Prior art keywords
okaperidone
relates
present
okaperidon
composition containing
Prior art date
Application number
EA200701741A
Other languages
English (en)
Other versions
EA013596B1 (ru
Inventor
Сатиш Кханна
Цезарь Мондадори
Стефано Бионди
Арнольд Демайи
Жан-Лоран Папарэн
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200701741A1 publication Critical patent/EA200701741A1/ru
Publication of EA013596B1 publication Critical patent/EA013596B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к композиции, содержащей окаперидон (как активное вещество) и водорастворимые полимеры в количестве, эффективном для повышения растворимости окаперидона. Кроме того, настоящее изобретение относится к терапевтической системе окаперидона, содержащей компартмент для лекарственной формы, содержащей указанную композицию, а также к процессу ее приготовления и к терапевтическому использованию указанной композиции в качестве антипсихотического лекарства. Настоящее изобретение также относится к солюбилизации окаперидона в водной среде с помощью водорастворимых набухающих полимеров.
EA200701741A 2005-02-15 2006-02-15 Фармацевтическая система доставки, содержащая окаперидон EA013596B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05290332A EP1690540A1 (en) 2005-02-15 2005-02-15 Composition comprising ocaperidone
PCT/IB2006/000758 WO2006087639A1 (en) 2005-02-15 2006-02-15 Composition comprising ocaperidone

Publications (2)

Publication Number Publication Date
EA200701741A1 true EA200701741A1 (ru) 2007-12-28
EA013596B1 EA013596B1 (ru) 2010-06-30

Family

ID=34981863

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701741A EA013596B1 (ru) 2005-02-15 2006-02-15 Фармацевтическая система доставки, содержащая окаперидон

Country Status (12)

Country Link
US (2) US20080103159A1 (ru)
EP (2) EP1690540A1 (ru)
JP (1) JP2008530080A (ru)
KR (1) KR20070102557A (ru)
CN (1) CN101128203A (ru)
AU (1) AU2006215309B2 (ru)
BR (1) BRPI0608083A2 (ru)
CA (1) CA2595269A1 (ru)
EA (1) EA013596B1 (ru)
MX (1) MX2007009916A (ru)
NZ (1) NZ556626A (ru)
WO (1) WO2006087639A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011067296A1 (en) 2009-12-01 2011-06-09 Integragen A combination of eight risk alleles associated with autism
WO2014042657A1 (en) 2012-09-17 2014-03-20 Halliburton Energy Services, Inc. Well tools with semi-permeable barrier for water-swellable material

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DE3868077D1 (de) * 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
IT210468Z2 (it) 1987-01-21 1988-12-30 Iveco Fiat Attuatore lineare elettromeccanico per il ribaltamento della cabina di guida di un veicolo industriale
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
US7767708B2 (en) * 1998-11-04 2010-08-03 Schering-Plough Animal Health Corp. Growth stimulant compositions
AU5060499A (en) * 1999-08-04 2001-03-05 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
IN190699B (ru) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US6713479B2 (en) * 2001-03-02 2004-03-30 Sepracor Inc. Piperidine-piperazine ligands for neurotransmitter receptors
EP1411901B1 (en) * 2001-07-04 2010-08-18 Sun Pharma Advanced Research Company Ltd Gastric retention controlled drug delivery system
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract

Also Published As

Publication number Publication date
AU2006215309B2 (en) 2011-03-24
AU2006215309A1 (en) 2006-08-24
BRPI0608083A2 (pt) 2009-11-10
KR20070102557A (ko) 2007-10-18
US20080103159A1 (en) 2008-05-01
CA2595269A1 (en) 2006-08-24
JP2008530080A (ja) 2008-08-07
EP1690540A1 (en) 2006-08-16
EA013596B1 (ru) 2010-06-30
US20120009266A1 (en) 2012-01-12
WO2006087639A1 (en) 2006-08-24
NZ556626A (en) 2009-09-25
EP1861103A1 (en) 2007-12-05
MX2007009916A (es) 2007-09-25
CN101128203A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
NO20075136L (no) Nye liposompreparater
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
BRPI0511466A (pt) agonistas peptìdicos do receptor de vasopressina
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AR047928A1 (es) Derivados de tetrahidropiridoindol
BRPI0406801A (pt) Derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
NO20075111L (no) Farmasoytisk sammensetning
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA200900900A1 (ru) Производные замещенных 3-фенил-1-(фенилтиенил)пропан-1-онов и 3-фенил-1-(фенилфуранил)пропан-1-онов, их получение и применение
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU